HIGHLIGHTS
- who: MEETING REPORT and collaborators from the (UNIVERSITY) have published the article: Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia, in the Journal: (JOURNAL)
- what: The study demonstrated excellent efficacy with acalabrutinib in treatment-naïve cll, achieving a 97% orr and an efs rate of 90% at 48 months. Cardiac event Atrial fibrillation Ventricular tachyarrhythmias Author Conclusions: This study provides the longest safety and efficacy follow-up to date for acalabrutinib monotherapy in symptomatic patients with treatment-naïve cll. The study showed that orr and pfs were superior for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.